A Phase 3 interventional study of estradiol, 25 mcg in Menopause and Urinary Infections, sponsored by Novo Nordisk A/S. Terminated at 1 site in Sweden. Open to female participants. Per ClinicalTrials.gov, last updated 2017-02-28.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
This trial is conducted in Europe. The aim of this trial is to investigate the preventive effect of treatment with estradiol vaginal tablets on recurrent urinary tract infections (RUTI) in post-menopausal women with signs of urogenital ageing (UGA).
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 6 is below the median of 120 across 4,200 interventional studies indexed under Infections.
Browse Infections studies →Novo Nordisk A/S is the lead sponsor of 1,370 studies on the registry; 102 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 94 (47%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Time to first symptom of urinary tract infection (UTI)
Number of urinary tract infection (UTI)
Time frame: During the 12 months of treatment
This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novo Nordisk A/S